SUPERFICIAL BLADDER CANCER: THE ROLE OF INTERFERON-alpha
Authors:
- John R. FranklinJFJohn R. Franklin
- Michael A. O'DOnnellMOMichael A. O'DOnnell
- Leonard G. GomellaLGLeonard G. Gomella
- Eric KleinEKEric Klein
- Rudolph NeriRNRudolph Neri
- Unyime O. NseyoUNUnyime O. Nseyo
- Timothy L. RatliffTRTimothy L. Ratliff
- Richard D. WilliamsRWRichard D. Williams
- 1 June 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 159 (6) , 1793-1801
Abstract
We evaluate the clinical experience with recombinant interferon-alpha in superficial transitional cell carcinoma and discuss the most rational use of recombinant interferon-alpha in the context of current treatment options. The available data were reviewed and discussed at a consensus conference in August 1996. The conclusions and recommendations are those of the authors based on the consensus reached at that meeting. While bacillus Calmette-Guerin (BCG) is recognized as the most efficacious intravesical agent in the prophylaxis and treatment of superficial transitional cell carcinoma, it is associated with significant toxicities and a 20 to 40% relapse rate. Interferons, particularly recombinant interferon-alpha, have demonstrated efficacy against primary and recurrent papillary transitional cell carcinoma and carcinoma in situ with minimal toxicity, although the response and relapse rates are inferior to BCG. Intravesical recombinant interferon-alpha therapy has also produced responses in patients who failed to respond or were refractory to BCG or chemotherapy. The clinical experience suggests that recombinant interferon-alpha has an important role in the treatment of superficial transitional cell carcinoma, particularly as second line therapy following failure of BCG or chemotherapy, and it may have synergistic effects when combined with chemotherapy or BCG. We propose a prospective randomized study comparing the efficacy of recombinant interferon-alpha, BCG and BCG plus recombinant interferon-alpha as maintenance following complete response to primary BCG therapy. The proposed study would also investigate the efficacy of BCG plus recombinant interferon-alpha as second line therapy following BCG failure. This study will be important to determine the most effective strategy to integrate recombinant interferon-alpha into current treatment options for superficial bladder cancer.Keywords
This publication has 59 references indexed in Scilit:
- Determination of Interferon-alpha Receptors in Urothelial Cancer and in Normal UrotheliumJournal of Urology, 1997
- Evaluation of local immune response after intravesical bacille Calmette‐Guérin treatment for superficial bladder cancerBritish Journal of Urology, 1996
- The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapyCancer Immunology, Immunotherapy, 1993
- A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladderEuropean Journal of Cancer, 1993
- Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancerCancer Immunology, Immunotherapy, 1992
- Immunomodulatory effect of interferon-α2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladderAnti-Cancer Drugs, 1992
- How Effective is Topical Alpha‐2b Interferon in Preventing Recurrence of Superficial Bladder Cancer?British Journal of Urology, 1991
- Clinical Studies on Cell‐mediated Immunity in Patients with Urinary Bladder Carcinoma: Blastogenic Response, Interleukin‐2 Production and Interferon‐y Production of LymphocytesBritish Journal of Urology, 1990
- Intravesical treatment of bladder cancer with recombinant human interferon-βCancer Immunology, Immunotherapy, 1989
- Interferon Therapy in Neoplastic DiseaseActa Medica Scandinavica, 1978